DK1133295T3 - Anvendelse af nicergolin ved behandling af spasticitet - Google Patents

Anvendelse af nicergolin ved behandling af spasticitet

Info

Publication number
DK1133295T3
DK1133295T3 DK99956108T DK99956108T DK1133295T3 DK 1133295 T3 DK1133295 T3 DK 1133295T3 DK 99956108 T DK99956108 T DK 99956108T DK 99956108 T DK99956108 T DK 99956108T DK 1133295 T3 DK1133295 T3 DK 1133295T3
Authority
DK
Denmark
Prior art keywords
nicergoline
spasticity
treatment
pathology
treating
Prior art date
Application number
DK99956108T
Other languages
Danish (da)
English (en)
Inventor
Michel Dib
Vincent Meininger
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1133295T3 publication Critical patent/DK1133295T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Soil Working Implements (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99956108T 1998-11-24 1999-11-22 Anvendelse af nicergolin ved behandling af spasticitet DK1133295T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9814794A FR2786101B1 (fr) 1998-11-24 1998-11-24 Utilisation de la nicergoline dans le traitement de la spasticite
PCT/FR1999/002866 WO2000030642A1 (fr) 1998-11-24 1999-11-22 Utilisation de la nicergoline dans le traitement de la spasticite

Publications (1)

Publication Number Publication Date
DK1133295T3 true DK1133295T3 (da) 2003-12-22

Family

ID=9533131

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99956108T DK1133295T3 (da) 1998-11-24 1999-11-22 Anvendelse af nicergolin ved behandling af spasticitet

Country Status (11)

Country Link
US (2) US6380208B2 (pt)
EP (1) EP1133295B1 (pt)
JP (1) JP4936594B2 (pt)
AT (1) ATE248596T1 (pt)
AU (1) AU1278500A (pt)
DE (1) DE69911052T2 (pt)
DK (1) DK1133295T3 (pt)
ES (1) ES2201801T3 (pt)
FR (1) FR2786101B1 (pt)
PT (1) PT1133295E (pt)
WO (1) WO2000030642A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
YU39278B (en) * 1976-12-22 1984-10-31 Lek Tovarna Farmacevtskih Process for preparing 5-bromo nicotinic acid esters
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IT1252163B (it) * 1991-12-03 1995-06-05 Poli Ind Chimica Spa Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica
JP2864885B2 (ja) * 1992-07-02 1999-03-08 田辺製薬株式会社 ニセルゴリン含有経口投与製剤
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
IT1256743B (it) * 1992-12-18 1995-12-15 Giorgio Pifferi Composizioni farmaceutiche a rilascio controllato contenenti nicergolina
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
DE19842416A1 (de) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden
FR2786099B1 (fr) * 1998-11-24 2000-12-29 Aventis Laboratoire Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
FR2786100B1 (fr) * 1998-11-24 2002-03-01 Aventis Laboratoire Nouvelle application therapeutique de la nicergoline
US6297254B1 (en) * 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease

Also Published As

Publication number Publication date
US6713493B2 (en) 2004-03-30
FR2786101A1 (fr) 2000-05-26
AU1278500A (en) 2000-06-13
US20020086875A1 (en) 2002-07-04
JP2003530298A (ja) 2003-10-14
ATE248596T1 (de) 2003-09-15
DE69911052T2 (de) 2004-08-19
JP4936594B2 (ja) 2012-05-23
FR2786101B1 (fr) 2002-07-05
EP1133295B1 (fr) 2003-09-03
DE69911052D1 (de) 2003-10-09
PT1133295E (pt) 2004-01-30
ES2201801T3 (es) 2004-03-16
US20020013332A1 (en) 2002-01-31
EP1133295A1 (fr) 2001-09-19
WO2000030642A1 (fr) 2000-06-02
US6380208B2 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DE50113396D1 (de) System zur gezielten Deformation von optischen Elementen
MXPA03002813A (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias.
NO20000688D0 (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
AU3831301A (en) Method for treating ocular pain
WO2002030353A3 (en) NF-λB INHIBITORS
BR9812837A (pt) Processo para fazer um composto, e, composto
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
BR0106411B1 (pt) processo de tratamento do lìquido residual de cromatização.
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DK1133295T3 (da) Anvendelse af nicergolin ved behandling af spasticitet
ES2141330T3 (es) Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina.
EP1315503A4 (en) TREATMENT OF URINARY DISORDER
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.
PL373490A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
DE60005566D1 (de) Pyranoindole zur glaukombehandlung
NO20005548D0 (no) Mykobakterieinhibitorer
PT1225890E (pt) Rivastigmina para o tratamento de doencas oculares
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
DE60037889D1 (de) Ionbehandlung für Schmuckgegenstand
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.